Last reviewed · How we verify

Topical Lidocaine

Aultman Health Foundation · FDA-approved active Small molecule

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Topical anesthesia for minor cuts, wounds, and abrasions, Relief of pain and itching from minor skin irritations, Temporary numbing of skin prior to minor procedures.

At a glance

Generic nameTopical Lidocaine
Also known asTopical anesthetic, Topical, Versatis 5% Medicated Plaster, PL21727/0016., lidocaine gel, numbing gel, LMX-4
SponsorAultman Health Foundation
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaPain management / Anesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that works by inhibiting sodium influx through sodium-selective channels in the nerve cell membrane, thereby blocking the generation and propagation of action potentials. When applied topically, it anesthetizes the area of application by preventing sensory nerve signals from reaching the central nervous system. This results in temporary loss of sensation in the treated region without affecting consciousness or motor function.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: